Researchers report significant progress toward expanding the therapeutic options available for people with non-cancerous blood conditions in five studies presented during the 66th American Society of ...
In the pivotal LUNA 3 study, adult patients with persistent or chronic ITP and severely low platelet counts (median of 15,000/μL) received oral rilzabrutinib 400 mg twice a day (n=133) or placebo ...